Amitifadine

DB05964InvestigationalSmall molecule

Investigated for use/treatment in depression.

Mechanism: DOV 21947 exhibits antidepressant-like properties as well as potent analgesic activity. It inhibits reuptake of the three neurotransmitters most closely linked to depression - serotonin, norepinephrine and dopamine - can produce greater overall efficacy than currently marketed antidepressants.
Curator reviewed
Primary indication: Investigated for use/treatment in depression.Curator reviewed
Formula / weight: C₁₁H₁₁Cl₂N · 228.12 g/mol (avg)
Code names: DOV-21947 · EB-1010

Resolves to

Compound

Structure

InChIKeyBSMNRYCSBFHEMQ-KCJUWKMLSA-NSMILES[H][C@]12C[C@]1(CNC2)C1=CC(Cl)=C(Cl)C=C1

Targets

What you can answer from here — as of September 16, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Amitifadine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.